Immutep Receives ~A$0.86 Million R&D Tax Incentive

SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’…